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Abstract
Dose constraints for traditional neural critical structures (e.g. optic chiasm, brain stem) are a standard component of
planning radiation therapy to the central nervous system. Increasingly, investigators are becoming interested in accounting
for the dose delivered to other non-target neural structures (e.g. hippocampi), which are not easily identified on axial
imaging. In this pilot study, a commercially available digital atlas was used to identify cryptic neural structures
(hippocampus, optic radiations, and visual cortices) in 6 patients who received intensity modulated radiation therapy (IMRT)
as part of multimodal management of glioblastoma multiforme (GBM). The patient’s original IMRT plans were re-optimized,
with avoidance parameters for the newly identified critical structures. Re-optimization was able to reduce both mean and
maximum dose to the volumes of interest, with a more pronounced effect for contralateral structures. Mean dose was
reduced by 11% and 3% to contralateral and ipsilateral structures, respectively, with comparable reduction in maximum
dose of 10% and 2%, respectively. Importantly, target coverage was not compromised, with an average change in coverage
of 0.2%. Overall, our results demonstrate the feasibility of incorporating tools for cryptic critical structure identification into
the treatment planning process for GBM.
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Introduction
Malignant gliomas represent the most common primary central
nervous system (CNS) malignancy in adults, with anaplastic
astrocytoma (AA) and glioblastoma multiforme (GBM) accounting
for 60% of malignant CNS gliomas [1]. Radiation therapy is a
cornerstone of treatment for these neoplasms, and, owing to the
diffusely infiltrative nature of these tumors, large treatment volumes
are often required to deliver optimal treatment. While the prognosis
for high-grade glioma generally remains poor, with the advent of
concurrent temozolamide (TMZ) therapy [2,3,4], and the identifica-
tion of 1p19q loss of heterozygosity [5,6,7] and IDH1 mutations [8] as
favorable prognostic indicators, there are now subsets of patients for
whom the median survival is predicted to be measured in years. As the
ability to identify these patients with favorable responses improves,
minimizing iatrogenic neurotoxicity will be of growing importance.
Planning radiation treatment to the CNS involves the
delineation of critical organ at risk structures, such as the optic
chiasm, brainstem, and cochlea, in order to reduce the risk of
treatment toxicity. However, while structures such as the chiasm
are readily identifiable on axial imaging, other structures at
potential risk, such as the optic radiations, hippocampi, or visual
cortices, are not readily segmented using conventional planning
systems. Thus, we sought to demonstrate the feasibility of using a
deformable anatomic digital atlas as a tool to aid in identifying and
contouring these cryptic neural structures. Here we present the
results of a pilot studying applying this technique to six patients
who underwent radiation treatment for GBM.
Materials and Methods
Patient characteristics
After obtaining institutional IRB approval for retrospective
dosimetric analysis, the treatment plans of 6 patients treated for
high-grade glioma at the University of Texas MD Anderson
Cancer Center between 2008 and 2010 were selected for analysis.
5 patients were treated for primary disease, and 1 patient was
treated for recurrent disease. Patient characteristics are summa-
rized in Table 1. No external funding was received for this study.
Treatment Planning and Target Volumes
Pinnacle treatment planning software (Version 9) with Direct
Machine Parameter Optimization (DMPO) was used for treat-
ment planning. For patients with primary tumors, the patient’s
pre-operative contrast-enhanced MRI was registered with the
treatment planning CT scan obtained at the time of simulation, to
aid in delineation of the clinical target volume (CTV). A high-dose
CTV (CTV1) was identified, comprising the surgical cavity, as well
as the areas of contrast enhancement and areas of FLAIR signal
abnormality deriving from tumor infiltration. CTV1 was uni-
formly expanded by 5 mm to account for set-up uncertainty – this
expansion created a planning target volume (PTV), termed ‘‘Boost
PTV,’’ which was planned to receive 60 Gy in 30 fractions. To
create the low-dose CTV (CTV2), CTV1 was uniformly expanded
by 2 cm, and contours were then edited to exclude air, bone, and
brain parenchyma protected by anatomic barriers. A 5 mm
uniform expansion for set-up uncertainty was performed, with the
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Intensity modulated radiation therapy (IMRT) treatment plans
were designed to deliver a simultaneous integrated boost (2 Gy per
fraction to ‘‘Boost PTV’’ and ,1.66 Gy per fraction to ‘‘PTV50’’).
A representative treatment plan is illustrated in Figure 1. For the 1
patient with recurrent disease (and a history of prior radiation for
his primary disease), gross recurrent disease was contoured, and
expanded 5 mm for set-up uncertainty – the resultant PTV was
planned for 40 Gy in 20 fractions.
Organ at risk (OAR) segmentation
Anatom-E (Houston, TX) is a commercially available deform-
able anatomic digital atlas [9] which provides axial MRI imaging
with functional annotation of CNS structures validated with
intraoperative neurosurgical data (J. Pagani, personal communi-
cation). We used the Anatom-E atlas to aid in delineation of the
optic radiations, visual cortices, and hippocampi. To accomplish
this, the Pinnacle treatment planning display console was mirrored
to the Anatom-E display. Software image controls allow blending
of MRI images (for ease of registration) and wireframe structural
anatomy (for display of functional areas and white matter tracts),
as shown in Figure 2. The deformable anatomic atlas was
registered to the planning CT and pre-operative MRI images. To
accomplish this, the atlas template was manually deformed on a
slice by slice basis using an affine (linear) transformation, which
allows compensation for variation in brain dimensions and patient
head position, with the surfaces of the cerebral hemispheres
serving as a landmark. The highly constant central sulcus was used
to verify alignment as previously described [10,11]. Selected
structures were contoured based on the atlas guideline (Figure 3).
In 3 patients, ipsilateral OAR structures were impacted by
resection defects or gross disease: patient 1 – gross recurrent
disease abutted ipsilateral OARs with minimal mass effect, patient
4 – the surgical cavity abutted a small section of the optic
radiations anteriorly, patient 6 - resected disease prevented the
contouring of the ipsilateral optic radiations. Contralateral
structures were unaffected in all patients.
IMRT treatments were then re-planned, incorporating the
newly identified volumes as avoidance structures using soft
constraints designed to reduce OAR dose without compromising
tumor coverage. In order to accomplish this, the original beam
arrangement and isocenter were preserved, as were the initial
optimization parameters. Additional optimization structures for
each critical structure were created and set approximately 10–20%
lower than the dose delivered by the original plan. Progressive
rounds of optimization were performed until the optimization
results began to yield plans with inadequate prescription dose
coverage (,95% target volume). At this point, OAR objectives
were relaxed to restore tumor coverage. Overall, the additional
optimization procedures added approximately 2 hours to the
planning time for a given patient.
Results
Re-optimization of the IMRT treatment plans generated new
treatment plans that reduced dose to the identified OARs. A
Table 1. Patient characteristics.
Pt Age Gender Tumor type Location GTV PTV
1 63 M GBM (recurrent) R temporal lobe 123 cc 185 cc
2 50 F GBM R frontal lobe 17 cc 251 cc
3 56 M GBM R frontal lobe 80 cc 564 cc
4 60 F GBM R basal ganglia 19 cc 297cc
5 62 F GBM R temporal lobe 101 cc 482 cc
6 62 F GBM L parietal lobe 38 cc 454 cc
doi:10.1371/journal.pone.0032098.t001
Figure 1. Diagnostic imaging and treatment plan from a representative case. A) Pre-operative contrast enhanced MRI. B) Post-operative
contrast enhanced MRI showing resection cavity. C) Treatment planning CT with isodose lines depicting the dose distribution.
doi:10.1371/journal.pone.0032098.g001
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histogram analysis (DVH) demonstrating shifts in the dose-volume
curves following re-optimization. A qualitative dose-reduction
effect was more pronounced for OARs contralateral to the tumor
bed.
In order to quantify the degree of dose-reduction, we analyzed
the change in mean dose and maximum dose to critical structures
after re-optimization. With regard to mean dose, an average dose
reduction of 3% was achieved for critical structures ipsilateral to
the tumor bed (range 0%–16%). The ability to reduce dose to
ipsilateral structures was limited by the need to preserve tumor
coverage – in many cases, these ipsilateral structures lay within or
in immediate proximity to the tumor bed. However, as
anticipated, the effect of re-optimization on contralateral struc-
tures was more pronounced – an average dose reduction of 11%
was achieved for critical structures contralateral to the tumor bed,
with 93% of these structures showing some dose reduction (range
0.4% increase to 22% reduction). Generally, the visual cortices
were located at the greatest distance from the tumor bed – these
structures correspondingly enjoyed the greatest magnitude of dose
reduction (Figure 5). Importantly, the goal of critical structure
sparing did not compromise tumor coverage – the average change
in dose to the PTV was a 0.2% increase (range 0.7% decrease to
0.9% increase). Analysis of reduction in maximum dose to OARs
revealed similar results, albeit with somewhat more modest
reductions (average reduction of 2.4% to ipsilateral structures
and 9.7% to contralateral structures).
Discussion
Strategies to reduce iatrogenic neurotoxicity secondary to CNS
irradiation have been of longstanding interest, and in recent years,
growing attention has been given to efforts to assess and avert
adverse neurocognitive outcomes in a variety of clinical situations
(e.g. dose reduction for patients with primary CNS lymphoma
[12], and SRS alone for patients with 1–3 brain metastases
[13,14]).
In addition to dose reduction where appropriate, an additional
strategy under active investigation is that of reducing unnecessary
dose to functional neural pathways. An ongoing trial administered
by the Radiation Therapy Oncology Group (RTOG) – RTOG
0933 – examines the potential benefit of hippocampal avoidance
for patients undergoing whole brain radiation therapy (WBRT) for
cancers metastatic to the brain. This trial seeks to test whether
IMRT techniques that spare the hippocampus will yield improved
neurocognitive outcomes. The patient population for this study
includes patients with a RTOG brain metastasis recursive
partitioning analysis (RPA) class of I–II – translating to a median
Figure 2. Anatom-E digital atlas. For structure delineation, the display of treatment planning system (Pinnacle) is mirrored to a second computer
monitor, and the Anatom-E images are superimposed (A) and adjusted and scaled to achieve registration with the planning CT images. Anatom-E
software controls allow blending (B) of the MRI and wireframe views for ease of registration and structure identification.
doi:10.1371/journal.pone.0032098.g002
Figure 3. Identification of cryptic critical structures. In A) the
overlay of the Anatom-E atlas and planning CT is illustrated. In B), the
atlas image has been turned off, leaving the structures alone
superimposed on the planning CT. Panel C shows the overlay with
the pre-treatment MRI, and Panel D depicts the atlas images turned off,
with the resultant contours on the planning CT.
doi:10.1371/journal.pone.0032098.g003
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survival of GBM patients, by contrast, ranges from 12–17 months
[2,3] suggesting that efforts to reduce potential neurocognitive
effects of radiation are appropriate in this population as well.
Two recent reports also explore the feasibility of accounting for
dose to non-traditional OARs in treatment planning for high-
grade glioma. As part of an analysis of advanced treatment
delivery technologies, a Danish study [16] examined the dose
delivered to the hippocampi from IMRT plans compared to
treatment planning with inversely optimized rotational therapy
(RapidArc) and intensity modulated proton therapy (IMPT).
Details on the delineation of the hippocampal OAR were not
specified, but the authors found that IMPT plans gave the lowest
average dose to the contralateral hippocampus. Treatment
planning results in the absence of efforts to spare the hippocampus
were not described, precluding quantification of what dose
reduction was achieved. Another recent study from Marsh et al
[17] examined sparing of the limbic system, hippocampus and
neural stem-cell niches in high-grade glioma. This study used more
stringent optimization criteria, setting a maximum dose of 8 Gy to
the contralateral hippocampus, and reported a more dramatic
reduction of dose to the contralateral hippocampus (57%
reduction in mean dose). However, this analysis is not directly
comparable to the present study, as the inclusion of the posterior
optic radiations as avoidance structures in this analysis affects the
ability to minimize dose to multiple geographic regions of the
brain.
Additionally, while several guidelines for hippocampal sparing
have been published in the clinical literature [18,19], this complex
structure still requires expertise for accurate segmentation – as
Figure 4. Re-optimized treatment plans reduce dose to cryptic OARs. A) Comparison of isodose lines on an axial slice from a representative
patient. B) Dose-volume histogram analysis for the plan depicted in (A).
doi:10.1371/journal.pone.0032098.g004
Figure 5. Re-optimization reduces mean and maximum dose parameters. The average percent reduction in mean (left panel) and maximum
(right panel) dose is shown for the ipsilateral and contralateral visual cortices, hippocampi (hip.) and optic radiations (OR). Error bars represent the
standard error of the mean.
doi:10.1371/journal.pone.0032098.g005
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review of hippocampal OAR contours. Our work demonstrates
the feasibility of using a deformable registration tool to accomplish
the delineation of this structure – previous dosimetric studies do
not provide detailed descriptions of the methods used to identify
the hippocampi. Additionally, to our knowledge, this study is the
first to include analysis of dose avoidance to the posterior optic
pathways, for which there are no consensus contouring guidelines.
Owing to the extensive annotation of the digital anatomic atlas,
this technique could be extended to include other functional areas
as desired.
Ultimately, as data on neurocognitive effects of radiation
therapy emerge from ongoing clinical investigations, and knowl-
edge of functional neuroanatomy is further supplemented with
improvements in functional imaging, accounting for dose
delivered to these circuits will become increasingly important in
radiation oncology treatment planning. Our study reduced dose to
multiple OARs simultaneously while preserving target coverage.
As data regarding the clinical effects of cryptic OAR sparing
approaches emerges, treatment planning objectives can be altered
accordingly in pursuit of dose reductions of larger magnitude for
an individualized clinical scenario.
Future studies will help define the risk-benefit ratio of reduced
target coverage in favor of OAR preservation, as well as help
establish relative priorities for OAR preservation. Overall, our
work illustrates how a deformable anatomic atlas can be used to
reduce the dose delivered to cryptic critical structures – critical
structures that are not accounted for in conventional treatment
planning schema were identified and spared without compromis-
ing target coverage.
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